Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Eva L. Kneepkens¹, Dora pascual-Salcedo², Chamaida Plasencia³, Charlotte L. M. Krieckaert⁴, Desiree van der Kleij⁵, Michael T. Nurmohamed^4,6, Maria Teresa lópez-Casla⁷, Theo Rispens⁸ and Gertjan Wolbink^4,8, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunology unit, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Immunology, La Paz University Hospital, Madrid, Spain, ⁸Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…
Abstract Number: 1285 • 2013 ACR/ARHP Annual Meeting
Choline Kinase: A Novel Target For Rheumatoid Arthritis
Monica Guma¹, Elsa Sanchez-Lopez², Alessia Lodi³, Stefano Tiziani⁴, Juan Carlos Lacal⁵, Michael Karin⁶ and Gary S. Firestein⁷, ¹Rheumatology, UCSD School of Medicine, La Jolla, CA, ²Pharmacology, UCSD School of Medicine, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁵Oncology, University Hospital Fundacion Jimenez Diaz, Madrid, Spain, ⁶Departments of Pharmacology, UCSD School of Medicine, La Jolla, CA, ⁷Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Choline kinase (ChoKa) is an essential enzyme for phosphatidylcholine biosynthesis and is required for cell proliferation. The enzyme has also been implicated in cancer…
Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Susan C. Bolge¹, Roxanne Meyer² and Kathy Annunziata³, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, NY, ³Kantar Health, Princeton, NJ
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…
Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Christopher R. Holroyd^1,2, Brian Davidson³, Sarah Bennett³, David Waghorn³, Caron Underhil³, Cyrus Cooper², Antonia Calogeras³, Elaine M. Dennison⁴, Nicholas C. Harvey⁵, Ray Armstrong³, Stephan Gadola⁶ and Christopher J. Edwards^7,8, ¹Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ²MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁵University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁶University of Southampton, Southampton, United Kingdom, ⁷NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁸University of Southampton, Southampton, United Kingdom
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2811 • 2013 ACR/ARHP Annual Meeting
Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection
Ruchika Patel¹ and Joshua Baker², ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C (HCV) is estimated at 0.02%, affecting around 40,000 Americans. To our knowledge, no existing…
Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…
Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Ozgur Tunceli¹, Jeffrey R. Curtis², Tatia C. Woodward³, Siting Zhou¹, Yen-Wen Chen⁴ and Ancilla W. Fernandes³, ¹HealthCore, Inc., Wilmington, DE, ²Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ³MedImmune, LLC, Gaithersburg, MD, ⁴HealthCore, Inc, Wilmington, DE
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…
Abstract Number: 2126 • 2012 ACR/ARHP Annual Meeting
Changes of Serological Markers in the Course of Traditional and Biological Disease Modifying Therapy of Rheumatoid Arthritis
Christoph Böhler¹, Helga Radner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) are established markers in the diagnostic approach to rheumatoid arthritis (RA). Both auto-antibodies (AAB) also…
Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Stéphanie Emilie¹, Cécile Gaujoux-Viala², Benjamin Granger³, Anne-Christine Rat⁴, Bernard Combe⁵ and Bruno Fautrel⁶, ¹Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, ²Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…
Abstract Number: 1842 • 2012 ACR/ARHP Annual Meeting
Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America
Sameer Kotak¹, Andrew S. Koenig², David H. Collier³, Katherine C. Saunders⁴, Ping He⁵, Joel M. Kremer⁶ and George W. Reed⁷, ¹Specialty Care, Pfizer Inc., New York, NY, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Corrona, LLC., Southborough, MA, ⁵UMASS Medical School, Worcester, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Studies on patients with severe rheumatoid arthritis (RA) are widely reported. However, limited data are available on patients with moderate disease activity (MOD). Recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.